EMAIL THIS PAGE TO A FRIEND

Journal of leukocyte biology

Enhancement of neutrophil autophagy by an IVIG preparation against multidrug-resistant bacteria as well as drug-sensitive strains.


PMID 25908735

Abstract

Autophagy occurs in human neutrophils after the phagocytosis of multidrug-resistant bacteria and drug-sensitive strains, including Escherichia coli and Pseudomonas aeruginosa. The present study detected autophagy by immunoblot analysis of LC3B conversion, by confocal scanning microscopic examination of LC3B aggregate formation and by transmission electron microscopic examination of bacteria-containing autophagosomes. Patients with severe bacterial infections are often treated with IVIG alongside antimicrobial agents. Here, we showed that IVIG induced neutrophil-mediated phagocytosis of multidrug-resistant strains. Compared with untreated neutrophils, neutrophils exposed to IVIG showed increased levels of bacterial cell killing, phagocytosis, O(2)(-) release, MPO release, and NET formation. IVIG also increased autophagy in these cells. Inhibiting the late phase of autophagy (fusion of lysosomes with autophagosomes) with bafilomycin A1-reduced, neutrophil-mediated bactericidal activity. These findings indicate that autophagy plays a critical role in the bactericidal activity mediated by human neutrophils. Furthermore, the autophagosomes within the neutrophils contained bacteria only and their organelles only, or both bacteria and their organelles, a previously undocumented observation. Taken together, these results suggest that the contents of neutrophil autophagosomes may be derived from specific autophagic systems, which provide the neutrophil with an advantage. Thus, IVIG promotes the neutrophil-mediated killing of multidrug-resistant bacteria as well as drug-sensitive strains.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

CDS000370
(Octyloxy)benzene, AldrichCPR
C14H22O
A10809
4′-Hydroxy-3′-methoxyacetophenone, 98%
C9H10O3
W508454
Acetovanillone, ≥98%, FG
C9H10O3
SAB4200361
Anti-LC3B antibody, Mouse monoclonal, clone LC3B-6, purified from hybridoma cell culture
C2181 Anti-Mouse IgG (whole molecule) F(ab′)2 fragment–Cy3 antibody produced in sheep, affinity isolated antibody, buffered aqueous solution
F7512 Anti-Rabbit IgG (whole molecule)−FITC antibody produced in sheep, affinity isolated antibody, buffered aqueous solution
534102
Methylamine solution, 33 wt. % in absolute ethanol
CH5N
426466
Methylamine solution, 40 wt. % in H2O
CH5N
395048
Methylamine solution, 2.0 M in methanol
CH5N
395056
Methylamine solution, 2.0 M in THF
CH5N
658685
Os EnCat® 40, extent of labeling: 0.3 mmol/g Os loading
OsO4
O5500
Osmium tetroxide, Sealed ampule.
O4Os
75632
Osmium tetroxide solution, for electron microscopy, 4% in H2O
O4Os
75633
Osmium tetroxide solution, for electron microscopy, 2% in H2O
O4Os
T1378
Sigma 7-9®, ≥99% (titration), crystalline
C4H11NO3
W302600
Sodium citrate dihydrate, ≥99%, FG
C6H5Na3O7 · 2H2O
S4641
Sodium citrate tribasic dihydrate, ACS reagent, ≥99.0%
C6H5Na3O7 · 2H2O
C7254
Sodium citrate tribasic dihydrate, ≥98%
C6H5Na3O7 · 2H2O
C8532
Sodium citrate tribasic dihydrate, for molecular biology, ≥99%
C6H5Na3O7 · 2H2O
C3434
Sodium citrate tribasic dihydrate, BioXtra, ≥99.0% (titration)
C6H5Na3O7 · 2H2O
71402
Sodium citrate tribasic dihydrate, BioUltra, for molecular biology, ≥99.5% (NT)
C6H5Na3O7 · 2H2O
71405
Sodium citrate tribasic dihydrate, puriss. p.a., ACS reagent, ≥99.0% (NT)
C6H5Na3O7 · 2H2O
154563
Tris(hydroxymethyl)aminomethane, ultrapure grade, ≥99.9%
C4H11NO3
252859
Tris(hydroxymethyl)aminomethane, ACS reagent, ≥99.8%
C4H11NO3
S1804
Trisodium citrate dihydrate, meets USP testing specifications
C6H5Na3O7 · 2H2O
RDD008
Trizma® base, anhydrous, free-flowing, Redi-Dri, ≥99.9%
C4H11NO3
T1503
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline
C4H11NO3
T6066
Trizma® base, BioPerformance Certified, meets EP, USP testing specifications, cell culture tested, ≥99.9% (titration)
C4H11NO3
T6791
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
C4H11NO3
T4661
Trizma® base, ≥99.9% (titration), crystalline
C4H11NO3